FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103084501> ?p ?o ?g. }

• W2103084501 endingPage "5506" @default.
• W2103084501 startingPage "5496" @default.
• W2103084501 abstract "Abstract Purpose: Cisplatin and its platinum derivatives are first-line chemotherapeutic agents in the treatment of ovarian cancer; however, treatment is associated with tumor resistance and significant toxicity. Here we investigated the antitumoral activity of lipoplatin, one of the most promising liposomal platinum drug formulations under clinical investigation. Experimental Design: In vitro effects of lipoplatin were tested on a panel of ovarian cancer cell lines, sensitive and resistant to cisplatin, using both two-dimensional (2D) and 3D cell models. We evaluated in vivo the lipoplatin anticancer activity using tumor xenografts. Results: Lipoplatin exhibited a potent antitumoral activity in all ovarian cancer cell lines tested, induced apoptosis, and activated caspase-9, -8, and -3, downregulating Bcl-2 and upregulating Bax. Lipoplatin inhibited thioredoxin reductase enzymatic activity and increased reactive oxygen species accumulation and reduced EGF receptor (EGFR) expression and inhibited cell invasion. Lipoplatin demonstrated a synergistic effect when used in combination with doxorubicin, widely used in relapsed ovarian cancer treatment, and with the albumin-bound paclitaxel, Abraxane. Lipoplatin decreased both ALDH and CD133 expression, markers of ovarian cancer stem cells. Multicellular aggregates/spheroids are present in ascites of patients and most contribute to the spreading to secondary sites. Lipoplatin decreased spheroids growth, vitality, and cell migration out of preformed spheroids. Finally, lipoplatin inhibited more than 90% tumor xenograft growth with minimal systemic toxicity, and after the treatment suspension, no tumor progression was observed. Conclusion: These preclinical data suggest that lipoplatin has potential for clinical assessment in aggressive cisplatin-resistant patients with ovarian cancer. Clin Cancer Res; 20(21); 5496–506. ©2014 AACR." @default.
• W2103084501 created "2016-06-24" @default.
• W2103084501 creator A5006278471 @default.
• W2103084501 creator A5008340388 @default.
• W2103084501 creator A5016581593 @default.
• W2103084501 creator A5020517759 @default.
• W2103084501 creator A5056348965 @default.
• W2103084501 creator A5079213910 @default.
• W2103084501 date "2014-10-30" @default.
• W2103084501 modified "2023-09-29" @default.
• W2103084501 title "Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer" @default.
• W2103084501 cites W1507410482 @default.
• W2103084501 cites W1977258127 @default.
• W2103084501 cites W1980912158 @default.
• W2103084501 cites W1991106952 @default.
• W2103084501 cites W1997307146 @default.
• W2103084501 cites W2003738619 @default.
• W2103084501 cites W2004747958 @default.
• W2103084501 cites W2004748840 @default.
• W2103084501 cites W2019156893 @default.
• W2103084501 cites W2020153682 @default.
• W2103084501 cites W2024007204 @default.
• W2103084501 cites W2026862874 @default.
• W2103084501 cites W2044159336 @default.
• W2103084501 cites W2045545515 @default.
• W2103084501 cites W2046291524 @default.
• W2103084501 cites W2046940607 @default.
• W2103084501 cites W2047311008 @default.
• W2103084501 cites W2054879402 @default.
• W2103084501 cites W2066263765 @default.
• W2103084501 cites W2068854353 @default.
• W2103084501 cites W2074694798 @default.
• W2103084501 cites W2077945404 @default.
• W2103084501 cites W2078354424 @default.
• W2103084501 cites W2079968038 @default.
• W2103084501 cites W2084476833 @default.
• W2103084501 cites W2086793077 @default.
• W2103084501 cites W2090162098 @default.
• W2103084501 cites W2090459496 @default.
• W2103084501 cites W2091882385 @default.
• W2103084501 cites W2100926855 @default.
• W2103084501 cites W2104550697 @default.
• W2103084501 cites W2119646041 @default.
• W2103084501 cites W2121623154 @default.
• W2103084501 cites W2122396039 @default.
• W2103084501 cites W2129025128 @default.
• W2103084501 cites W2129320713 @default.
• W2103084501 cites W2131412185 @default.
• W2103084501 cites W2136484116 @default.
• W2103084501 cites W2155156801 @default.
• W2103084501 cites W2164909357 @default.
• W2103084501 cites W2415955117 @default.
• W2103084501 doi "https://doi.org/10.1158/1078-0432.ccr-14-0713" @default.
• W2103084501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25231401" @default.
• W2103084501 hasPublicationYear "2014" @default.
• W2103084501 type Work @default.
• W2103084501 sameAs 2103084501 @default.
• W2103084501 citedByCount "42" @default.
• W2103084501 countsByYear W21030845012015 @default.
• W2103084501 countsByYear W21030845012016 @default.
• W2103084501 countsByYear W21030845012017 @default.
• W2103084501 countsByYear W21030845012018 @default.
• W2103084501 countsByYear W21030845012019 @default.
• W2103084501 countsByYear W21030845012020 @default.
• W2103084501 countsByYear W21030845012021 @default.
• W2103084501 countsByYear W21030845012022 @default.
• W2103084501 countsByYear W21030845012023 @default.
• W2103084501 crossrefType "journal-article" @default.
• W2103084501 hasAuthorship W2103084501A5006278471 @default.
• W2103084501 hasAuthorship W2103084501A5008340388 @default.
• W2103084501 hasAuthorship W2103084501A5016581593 @default.
• W2103084501 hasAuthorship W2103084501A5020517759 @default.
• W2103084501 hasAuthorship W2103084501A5056348965 @default.
• W2103084501 hasAuthorship W2103084501A5079213910 @default.
• W2103084501 hasBestOaLocation W21030845011 @default.
• W2103084501 hasConcept C121608353 @default.
• W2103084501 hasConcept C126322002 @default.
• W2103084501 hasConcept C150903083 @default.
• W2103084501 hasConcept C185592680 @default.
• W2103084501 hasConcept C190283241 @default.
• W2103084501 hasConcept C207001950 @default.
• W2103084501 hasConcept C2776694085 @default.
• W2103084501 hasConcept C2777292972 @default.
• W2103084501 hasConcept C2778239845 @default.
• W2103084501 hasConcept C2780427987 @default.
• W2103084501 hasConcept C2781303535 @default.
• W2103084501 hasConcept C502942594 @default.
• W2103084501 hasConcept C55493867 @default.
• W2103084501 hasConcept C71924100 @default.
• W2103084501 hasConcept C86803240 @default.
• W2103084501 hasConcept C98274493 @default.
• W2103084501 hasConceptScore W2103084501C121608353 @default.
• W2103084501 hasConceptScore W2103084501C126322002 @default.
• W2103084501 hasConceptScore W2103084501C150903083 @default.
• W2103084501 hasConceptScore W2103084501C185592680 @default.
• W2103084501 hasConceptScore W2103084501C190283241 @default.
• W2103084501 hasConceptScore W2103084501C207001950 @default.
• W2103084501 hasConceptScore W2103084501C2776694085 @default.

• next